Jeffrey Eisele - 26 Dec 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Development Officer
Signature: /s/ David Watson, attorney-in-fact for Jeffrey Eisele
Issuer symbol: APLS
Transactions as of: 26 Dec 2023
Transactions value $: -$18,089
Form type: 4
Filing time: 28 Dec 2023, 16:13:12 UTC
Previous filing: 27 Feb 2023
Next filing: 17 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Sale	-$3,934	-68	-0.13%	$57.86	53,815	26 Dec 2023	Direct	F1
transaction	APLS	Common Stock	Sale	-$14,154	-235	-0.44%	$60.23	53,580	27 Dec 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This represents shares sold to cover tax withholding on a Restricted Stock Unit release.
F2	Sale originated from established 10b5-1 trading plan.